ArticleJournal of nephrology2017
How to improve duration and efficiency of the antiproteinuric response to Ramipril: RamiPROT-a prospective cohort study.
Article in Journal of nephrology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Current evidence on the use of anti-RAAS agents in congenital or acquired solitary kidney.Renal failure · 2017Pooled it
- Repurposing fexofenadine as a promising candidate for diabetic kidney disease: randomized clinical trial.International urology and nephrology · 2024Trial
- An open-label, randomized, placebo-controlled study on the effectiveness of a novel probiotics administration protocol (ProbiotiCKD) in patients with mild renal insufficiency (stage 3a of CKD).European journal of nutrition · 2019Trial
- Characteristics of hospitalized elderly patients with CKD: a comparison between elderly and non-elderly CKD based on a multicenter cross-sectional study.International urology and nephrology · 2024Article
- Fabry Disease in Women: Genetic Basis, Available Biomarkers, and Clinical Manifestations.Genes · 2023Review
- Impact of Thyroid Cancer Treatment on Renal Function: A Relevant Issue to Be Addressed.Journal of personalized medicine · 2023Review
- Stem Cells in Kidney Ischemia: From Inflammation and Fibrosis to Renal Tissue Regeneration.International journal of molecular sciences · 2023Review
- Atherosclerotic-nephropathy: an updated narrative review.Journal of nephrology · 2021Review
- Cystatin C, a Controversial Biomarker in Hypothyroid Patients under Levothyroxine Therapy: THYRenal, a Pilot Cohort Observational Study.Journal of clinical medicine · 2020Article
- Asymmetric dimethylarginine and angiopoietin-like protein-2 are independent predictors of cardiovascular risk in pre-dialysis non-diabetic chronic kidney disease patients.International urology and nephrology · 2020Article
- Secondary Hyperparathyroidism and Hypertension: An Intriguing Couple.Journal of clinical medicine · 2020Review
- ERK1,2 Signalling Pathway along the Nephron and Its Role in Acid-base and Electrolytes Balance.International journal of molecular sciences · 2019Review
- Evolution of glomerular filtration rates and neutrophil gelatinase-associated lipocalin during treatment with direct acting antivirals.Clinical and molecular hepatology · 2018Article
- Association between uremic toxin-anthranilic acid and fibrinolytic system activity in predialysis patients at different stages of chronic kidney disease.International urology and nephrology · 2018Article
- Persistent hematuria in patients with antineutrophil cytoplasmic antibody-associated vasculitis during clinical remission: chronic glomerular lesion or low-grade active renal vasculitis?BMC nephrology · 2017Article
- Granulomatous interstitial nephritis due to chronic lymphocytic leukemia: a case report.BMC nephrology · 2017Article
- Quality of life, clinical outcome, personality and coping in chronic hemodialysis patients.Renal failure · 2017Observational
- Relationship between plasma pentraxin 3 level and risk of chronic kidney disease in the Korean elderly: the Dong-gu study.International urology and nephrology · 2017Article
- Cathepsin L activity correlates with proteinuria in chronic kidney disease in humans.International urology and nephrology · 2017Observational
- Rare Renal Diseases Can Be Used as Tools to Investigate Common Kidney Disorders.Kidney diseases (Basel, Switzerland) · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe antiproteinuric pharmacokinetics of Ramipril in response to different doses and modalities of administration has been poorly investigated so far. STUDY
designProspective, open-label and not placebo controlled study. SETTING AND
participants40 Caucasian adult patients having GFR ≥ 50 mL/min, proteinuria 1-3 g/day; SBP/DBP ≤ 150/90 mmHg were recruited between June 2014 and November 2014. FACTOR AND OUTCOME: Impact on 24 h proteinuria and fractioned proteinuria of Ramipril given at different dosages (2.5 mg/day or Ramipril 5 mg/day or Ramipril 10 mg/day) and with different daily administration modalities (single or two divided doses) for cycles of 10 days. MEASUREMENTS: At the end of each cycle, 24 h and fractioned proteinuria on three timed urinary collections (morning, afternoon and night) were measured.
resultsCompared to baseline, Ramipril significantly reduced 24 h proteinuria at each dose and modality of administration. In particular, the greatest effects were evident with the higher and divided dose of the drug. The analysis of the fractioned proteinuria showed that the greatest reduction was obtained in the night urinary collection by administering Ramipril 10 mg/day in two divided doses. LIMITATIONS: Small sample size.
conclusionsRamipril reduces proteinuria at any of the tested doses. Although the using of high and divided doses seems to maximize the antiproteinuric effect of the drug, possibly due to a better pharmacological coverage of the nocturnal period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.